Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson's Disease [Yahoo! Finance]
Quest Diagnostics Incorporated (DGX)
Last quest diagnostics incorporated earnings: 4/22 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
ir.questdiagnostics.com
Company Research
Source: Yahoo! Finance
Global Phase 2 clinical trial leverages Roche-developed digital biomarker as primary endpoint for enhanced precision and efficiency over traditional clinical rating scales Collaborations with QIAGEN, Sano Genetics and Quest Diagnostics to streamline trial referrals and stratify patient subsets to identify those more likely to respond to treatment Company to initiate trial in early 2025, serving as major, value-creating catalyst for continued innovation across Neuron23's neuroimmunology pipeline SOUTH SAN FRANCISCO, Calif., November 19, 2024 BUSINESS WIRE )--Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today unveiled details around its global Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant, potent and selective inhibitor of LRRK2, in people with early Parkinson's disease (PD). The NEULARK trial represents a significant advancement in precision medicin
Show less
Read more
Impact Snapshot
Event Time:
DGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DGX alerts
High impacting Quest Diagnostics Incorporated news events
Weekly update
A roundup of the hottest topics
DGX
News
- $6.1 Bn Dietary Supplement Testing Services Global Market Opportunities and Strategies to 2033: Contaminant Testing Platforms, Adulteration Panel Analysis, AI-Driven Platforms for Improved Testing [Yahoo! Finance]Yahoo! Finance
- Quest Diagnostics (DGX) Up 2.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Quest Diagnostics Incorporated (NYSE: DGX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Vitamin D Testing Market Size to Reach USD 1774.70 Million by 2031 | SkyQuest Technology [Yahoo! Finance]Yahoo! Finance
- Should We Be Stressed About Our Cortisol Levels? I Got a Blood Stress Test to Find Out [CNET News]CNET News
DGX
Earnings
- 10/22/24 - Beat
DGX
Sec Filings
- 11/7/24 - Form 4
- 10/30/24 - Form 4
- 10/28/24 - Form 144
- DGX's page on the SEC website